公开(公告)号：WO2018148710A1

公开(公告)日：2018-08-16

申请号：PCT/US2018/017938

申请日：2018-02-13

Applicant: EXCISION BIOTHERAPEUTICS, INC.

Inventor： KHALILI, Kamel ,  YOUNG, Won-Bin

IPC: G01N33/569 ,  G01N21/76 ,  C12Q1/68 ,  C12Q1/70

CPC classification number: A61K49/0013 ,  A01K2227/105 ,  A01K2267/0337 ,  A01K2267/0393 ,  A61K31/7088 ,  A61K38/465 ,  A61K48/00 ,  A61K49/0097 ,  A61P31/18 ,  C12N2740/16043 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/397 ,  Y02A50/463 ,  Y02A50/467

Abstract: A reporter gene that can be administered to an individual such as HIV-BAL-eLuc in order to detect the presence of a virus. A method of detecting the presence of virus in an individual, by administering a reporter gene to the individual, associating the reporter gene with the virus, imaging the individual, and detecting the presence of virus in the individual. A method of determining the efficacy of a treatment for a virus, by administering a reporter gene to the individual receiving treatment for the virus, associating the reporter gene with the virus, imaging the individual, detecting the presence of virus in the individual, and determining if the treatment is effective.

公开(公告)号：WO2018051255A1

公开(公告)日：2018-03-22

申请号：PCT/IB2017/055547

申请日：2017-09-14

Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITED

Inventor： SASIKUMAR, Pottayil Govindan Nair ,  PRASAD, Appukkuttan ,  NAREMADDEPALLI, Seetharamaiah Setty Sudarshan ,  RAMACHANDRA, Muralidhara

IPC: C07D291/00 ,  C07D285/08 ,  A61K31/4245 ,  A61K31/433 ,  A61P31/00 ,  A61P35/00

CPC classification number: C07D271/113 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/497 ,  A61K31/519 ,  A61K31/5375 ,  A61P31/00 ,  A61P35/00 ,  C07D271/10 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  Y02A50/385 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/491

Abstract: The present invention relates to cyclic substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Abstract translation: 本发明涉及式（I）的环取代的1,3,4-恶二唑和噻二唑化合物及其用于抑制程序性细胞死亡1（PD1）信号传导途径和/或用于治疗 通过抑制由PD-1，PD-L1或PD-L2诱导的免疫抑制信号引起的疾病。

公开(公告)号：WO2017127755A1

公开(公告)日：2017-07-27

申请号：PCT/US2017/014449

申请日：2017-01-20

Applicant: FATE THERAPEUTICS, INC.

Inventor： ROSEN, Jonathan ,  REZNER, Betsy ,  VALAMEHR, Bahram ,  BJORDAHL, Ryan ,  PERALTA, Eigen

IPC: C12N5/0783 ,  C07K14/725 ,  A61K35/17

CPC classification number: A61K35/17 ,  A61K31/00 ,  A61K35/28 ,  A61K35/545 ,  A61K38/09 ,  A61K38/14 ,  A61K38/212 ,  A61K38/50 ,  C12N5/0636 ,  C12N2510/00 ,  Y02A50/467 ,  A61K2300/00

Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Abstract translation: 鉴定了产生更高比例或更高绝对数量的表型鉴定的中殿，干细胞记忆，中央记忆T细胞，适应性NK细胞和I型NKT细胞的化合物。 提供了用于调节免疫细胞（包括T，NK和NKT细胞）的过继细胞疗法的组合物和方法，其具有改善的功效。

公开(公告)号：WO2017075119A1

公开(公告)日：2017-05-04

申请号：PCT/US2016/058968

申请日：2016-10-27

Applicant: THE TRUSTEES OF THE UNIVERESITY OF PENNSYLVANIA

Inventor： WISON, James, M. ,  HINDERER, Christian ,  ROTHWELL, William, Thomas

IPC: C07K16/10 ,  C07K16/18 ,  C12N15/861 ,  A61P25/28 ,  A61K39/395 ,  A61K9/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/54 ,  C07K16/1063 ,  C07K2317/622 ,  C07K2317/71 ,  C12N15/861 ,  C12N2750/14143 ,  Y02A50/39 ,  Y02A50/467

Abstract: A composition comprising at least one AAV vector formulated for intrathecal delivery to the central nervous system is described. The composition comprises at least one expression cassette which contains sequences encoding an immunoglobulin construct linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn).

Abstract translation: 描述了包含至少一种配制用于鞘内递送至中枢神经系统的AAV载体的组合物。 该组合物包含至少一个表达盒，其含有编码与其表达控制序列连接的免疫球蛋白构建体的序列和药学上可接受的载体。 免疫球蛋白构建体可以是经修饰以对新生儿Fc受体（FcRn）具有降低的或不可测量的亲和力的免疫球蛋白。

公开(公告)号：WO2017060283A1

公开(公告)日：2017-04-13

申请号：PCT/EP2016/073760

申请日：2016-10-05

Applicant: UNIVERSITÄT BASEL

Inventor： HIRSCH, Hans H. ,  LEBOEUF, Céline

IPC: A61K38/16 ,  A61K39/12 ,  C07K14/025

CPC classification number: A61K39/12 ,  A61K38/16 ,  A61K2039/55 ,  A61K2039/57 ,  A61K2039/572 ,  C12N2710/14043 ,  C12N2710/22023 ,  C12N2710/22034 ,  Y02A50/467

Abstract: The invention relates to immunodominant peptide epitopes of BK, JC and MC polyomavirus; carriers, such as virus-like particles, virosomes or nanoparticles, comprising such peptide epitopes; vaccines against polyomavirus infection comprising such peptide epitopes and/or loaded carriers; and nucleic acids encoding these peptide epitopes. The invention further relates to diagnostic and therapeutic methods using these peptide epitopes in polyomavirus-associated diseases such as nephropathy or hemorrhagic cystitis of importance for transplant recipients.

Abstract translation: 本发明涉及BK，JC和MC多瘤病毒的免疫显性肽表位; 载体，如病毒样颗粒，病毒颗粒或纳米颗粒，包含这种肽表位; 包含这样的肽表位和/或载体载体的针对多瘤病毒感染的疫苗; 和编码这些肽表位的核酸。 本发明还涉及在多瘤病毒相关疾病如肾病或出血性膀胱炎中使用这些肽表位的移植受体重要性的诊断和治疗方法。

公开(公告)号：WO2017058795A1

公开(公告)日：2017-04-06

申请号：PCT/US2016/053965

申请日：2016-09-27

Applicant: AGENOVIR CORPORATION

Inventor： QUAKE, Stephen, R.

IPC: C12N15/11 ,  C12N15/63 ,  C12N9/22 ,  C12N9/14

CPC classification number: A61K38/465 ,  A61K47/549 ,  C12N9/22 ,  C12N15/1131 ,  C12N2310/20 ,  C12Y301/00 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467

Abstract: The invention provides compositions and methods that can be used to regulate viral transcription. Using a catalytically inactive nuclease such as deactivated Cas9, or dCas9, a guide RNA can be designed that recognizes a regulatory element within a viral nucleic acid. The dCas9 may function as an RNA-dependent DNA-binding protein that binds to a viral promoter and upregulates or down-regulates transcription. For example, the dCas9 with a viral promoter- specific gRNA may hybridize to a promoter within a viral genome within a host cell and inhibit transcription by, for example, sterically blocking recruitment of the transcription machinery.

Abstract translation: 本发明提供可用于调节病毒转录的组合物和方法。 使用催化无活性的核酸酶如失活的Cas9或dCas9，可以设计识别病毒核酸内调节元件的引导RNA。 dCas9可以作为结合病毒启动子并上调或下调转录的RNA依赖性DNA结合蛋白。 例如，具有病毒启动子特异性gRNA的dCas9可以与宿主细胞内的病毒基因组内的启动子杂交，并通过例如空间阻断募集转录机制来抑制转录。

公开(公告)号：WO2016201169A1

公开(公告)日：2016-12-15

申请号：PCT/US2016/036803

申请日：2016-06-10

Applicant: CITY OF HOPE ,  CALIFORNIA INSTITUTE OF TECHNOLOGY

Inventor： CANTIN, Edouard ,  MAZMANIAN, Sarkis, K. ,  RAMAKRISHNA, Chandran

IPC: A61K31/715 ,  A61K39/00 ,  A61K39/02 ,  C08B37/00

CPC classification number: A61K31/715 ,  A61K31/522 ,  A61K39/02 ,  C08B37/006 ,  C12N2710/16611 ,  Y02A50/394 ,  Y02A50/467 ,  A61K2300/00

Abstract: The present disclosure includes compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof) and methods of treating viral infection and viral infection associated inflammation with compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof).

Abstract translation: 本公开内容包括两性离子多糖（例如脆弱杆菌荚膜多糖A（PSA））（包括其活性片段）的组合物以及用两性离子多糖（例如，B）的组合物治疗病毒感染和病毒感染相关炎症的方法。 脆弱荚膜多糖A（PSA））（包括其活性片段）。

公开(公告)号：WO2015128492A1

公开(公告)日：2015-09-03

申请号：PCT/EP2015/054202

申请日：2015-02-27

Applicant: MAGHAZACHI, Azzam A.

Inventor： MAGHAZACHI, Azzam A.

IPC: A61K31/225 ,  A61P31/00 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

CPC classification number: A61K31/225 ,  Y02A50/467

Abstract: Compositions and methods for enhancing NK cell mediated killing of target cells, e.g., cancer cells, virally infected cells, among others, are provided. In one aspect, compositions and methods for treatment of cancer and/or infectious disease are provided.

Abstract translation: 提供了用于增强NK细胞介导的杀死靶细胞例如癌细胞，病毒感染细胞等的组合物和方法。 在一个方面，提供了用于治疗癌症和/或感染性疾病的组合物和方法。

公开(公告)号：WO2015059072A1

公开(公告)日：2015-04-30

申请号：PCT/EP2014/072398

申请日：2014-10-20

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1 ,  ENS - ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Inventor： LOTTEAU, Vincent ,  ANDRE, Patrice

IPC: A61K31/7068 ,  A61P31/20 ,  A61P13/12 ,  A61P35/00

CPC classification number: A61K31/7068 ,  A61K47/48038 ,  A61K47/48215 ,  A61K47/542 ,  A61K47/60 ,  Y02A50/467 ,  A61K2300/00

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of polyomavirus infections. In particular, the present invention relates to a method for treating a polyomavirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of gemcitabine.

Abstract translation: 本发明涉及用于治疗多瘤病毒感染的方法和药物组合物。 特别地，本发明涉及治疗有需要的个体的多瘤病毒感染的方法，包括给予受试者治疗有效量的吉西他滨。

公开(公告)号：WO2015033303A1

公开(公告)日：2015-03-12

申请号：PCT/IB2014/064283

申请日：2014-09-05

Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITED

Inventor： SASIKUMAR, Pottayil Govindan Nair ,  RAMACHANDRA, Muralidhara ,  NAREMADDEPALLI, Seetharamaiah Setty Sudarshan

IPC: A61K31/38 ,  A61K31/395 ,  C07D273/00 ,  C07D285/00

CPC classification number: C07K7/64 ,  A61K31/38 ,  A61K31/395 ,  A61K38/00 ,  C07D259/00 ,  C07D273/00 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481

Abstract: The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract translation: 本发明涉及循环拟肽化合物作为能够抑制程序性细胞死亡1（PD1）信号通路的治疗剂。 本发明还涉及治疗剂的衍生物。 本发明还包括所述治疗剂和衍生物用于通过免疫激活治疗疾病的用途，包括抑制由于PD-1，PD-L1或PD-L2引起的免疫抑制信号和使用它们的疗法。